Teladoc Health, Inc. · NYSE:TDOC

Teladoc Health — Q4 2024 Earnings Presentation

14 slides from Teladoc Health's earnings presentation, Feb 26, 2025

  1. Slide 1: 4Q-24 Quarterly Results

    4Q-24 Quarterly Results Teladoc HEALTH

  2. Slide 2: Cautionary Note

    Cautionary Note • This presentation contains, and the officers of Teladoc Health, Inc. (the “Company” or “Teladoc Health”) may make, “forward-looking” statements that are based on management’s beliefs and assumptions and on information currently available to management. These forward-looking stateme

  3. Slide 3: Financial Highlights

    Financial Highlights 4Q-24 Net loss per share of $(0.28) 4Q-24 Revenue of includes amortization of 4Q-24 Adj. $640M, (3)% y/y acquired intangibles of $(0.29) EBITDA(1) of and stock-based compensation expense of $(0.16) per share pre- $75M, (35)% y/y tax FY25 Revenue outlook range FY25 Net loss per s

  4. Slide 4: 4Q-24 Consolidated Revenue & Adj. EBITDA

    4Q-24 Consolidated Revenue & Adj. EBITDA Revenue ($ millions) Adj. EBITDA ($ millions)(1) 125 800 $114.4 $661 $640 100 600 $74.8 75 400 50 200 25 0 0 4Q-23 4Q-24 4Q-23 4Q-24 (1) See reconciliation of GAAP to non-GAAP measures included in the Appendix of this presentation. 4

  5. Slide 5: Quarterly Segment Results

    (1) Quarterly Segment Results Integrated Care Segment Revenue ($ millions) BetterHelp Segment Revenue ($ millions) 600 300 $276 $269 $265 $257 $250 $384 $377 $377 $384 $391 400 200 200 100 0 0 4Q-23 1Q-24 2Q-24 3Q-24 4Q-24 4Q-23 1Q-24 2Q-24 3Q-24 4Q-24 Integrated Care Segment Adjusted EBITDA ($ mill

  6. Slide 6: 4Q-24 Revenue: U.S. & International

    4Q-24 Revenue: U.S. & International U.S. Revenue ($ millions) International Revenue ($ millions) 600 125 $565 $535 $105 500 100 $96 400 75 300 50 200 25 100 0 0 4Q-23 4Q-24 4Q-23 4Q-24 6

  7. Slide 7: Quarterly Key Operating Metrics

    Quarterly Key Operating Metrics U.S. Integrated Care Members(1) (millions) BetterHelp Paying Users(2) (thousands) 100m 89.6 91.8 92.4 93.9 93.8 600k 425 415 407 398 400 400k 50m 200k 0m 0k 4Q-23 1Q-24 2Q-24 3Q-24 4Q-24 4Q-23 1Q-24 2Q-24 3Q-24 4Q-24 Average Revenue per Month per U.S. Chronic Care Pro

  8. Slide 8: Quarterly Trend: Adj. Gross Margin, Adj. EBITDA, & Adj. EBITDA Margin

    Quarterly Trend: Adj. Gross Margin, Adj. EBITDA, & Adj. EBITDA Margin GAAP Gross Margin & Adj. Gross Margin(1) Adj. EBITDA(1) & Adj. EBITDA Margin ($ millions) 125m 75% 17.3% 18% 71.9% 16% 70.7% 70.7% 70.5% 100m 13.9% 69.9% 13.0% 14% 70% 11.7% 12% 68.8% 75m 9.8% 67.2% 10% 66.7% 65% 65.8% 65.7% $114.

  9. Slide 9: Balance Sheet and Cash Flow Highlights

    Balance Sheet and Cash Flow Highlights • Cash and Cash Equivalents (as of December 31st, 2024): $1.30B • Convertible Senior Notes (as of December 31st, 2024): $1.54B • Operating Cash Flow (FY2024): $294M • Free Cash Flow (1) (FY2024): $170M (1) See reconciliation of GAAP to non-GAAP measures include

  10. Slide 10: Outlook: 1Q-25 and FY25

    Outlook: 1Q-25 and FY25 Y/Y % 1Q-25 Y/Y % Growth FY-25 Growth Revenue ($M) $608 to $629 (6)% to (3)% $2,468 to $2,576 (4)% to 0% Net loss per share $(0.40) to $(0.15) NM $(1.10) to $(0.50) NM Adj. EBITDA ($M) $47 to $59 (26)% to (6)% $278 to $319 (11)% to 3% US integrated care members (M) 101 to 102

  11. Slide 11: Appendix

    Teladc c. HEALTH © Appendix

  12. Slide 12: Reconciliation of Net Loss to Adjusted EBITDA

    Reconciliation of Net Loss to Adjusted EBITDA 4Q-23 1Q-24 2Q-24 3Q-24 4Q-24 Net loss $(28,890) $(81,889) $(837,671) $(33,276) $(48,409) Add: Provision for income taxes 3,515 2,690 3,884 780 238 Other expense (income), net (1,537) 370 563 (2,239) 7,341 Interest expense 5,538 5,649 5,648 5,660 6,846 I

  13. Slide 13: Reconciliation of GAAP Gross Profit to Adjusted Gross Profit

    Reconciliation of GAAP Gross Profit to Adjusted Gross Profit 4Q-23 1Q-24 2Q-24 3Q-24 4Q-24 Revenue $660,527 $646,131 $642,444 $640,508 $640,491 Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) (193,424) (194,538) (188,059) (179,745) (188,928) Amortizatio

  14. Slide 14: Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow

    Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow FY-24 Net cash provided by operating activities $293,680 Capital expenditures (10,790) Capitalized software development costs (113,262) Capex (124,052) Free Cash Flow $169,628 (in 000s) 14

Teladoc Health — Q4 2024 Earnings Presentation on 6ix